Literature DB >> 31660318

Is there an optimal "door to cath time" in the treatment of acute pulmonary embolism with catheter-directed thrombolysis?

Aranyak Rawal1, Devarshi Ardeshna2, Kirstin Hesterberg3, Brandon Cave4, Uzoma N Ibebuogu3, Rami N Khouzam3.   

Abstract

Ultrasound assisted catheter-directed thrombolysis (UACT) is a relatively novel approach to treating acute pulmonary embolism (PE). It is an alternative to systemic thrombolysis with good success rates and low reported in-hospital mortality, and low rates of procedure-related major and minor bleeding. Since UACT received FDA approval for the treatment of PE in 2014, there is paucity of data regarding the optimal timing of initiation of the procedure after the initial diagnosis is made. We reviewed the available literature regarding UACT for acute PE and found six studies that included time to procedure. Based on our review, patients may benefit from early (<24-48 h after presentation) rather than delayed (>48 h) initiation. Early initiation of therapy has shown to improve pulmonary arterial pressures, right ventricular (RV) to left ventricular (LV) ratios, with low rates of bleeding and low post procedural and in hospital mortality. However, further studies are required to confirm these findings and establish the appropriate timeline for initiation of UACT. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Acute pulmonary embolism (PE); Ekosonic endovascular system (EKOS), Time to ultrasound assisted catheter-directed thrombolysis (UACT); catheter-directed thrombolysis (CDT); ultrasound assisted catheter-directed thrombolysis (UACT)

Year:  2019        PMID: 31660318      PMCID: PMC6787388          DOI: 10.21037/atm.2019.07.89

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  41 in total

1.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Authors:  Gilles Montalescot; Leonardo Bolognese; Dariusz Dudek; Patrick Goldstein; Christian Hamm; Jean-Francois Tanguay; Jurrien M ten Berg; Debra L Miller; Timothy M Costigan; Jochen Goedicke; Johanne Silvain; Paolo Angioli; Jacek Legutko; Margit Niethammer; Zuzana Motovska; Joseph A Jakubowski; Guillaume Cayla; Luigi Oltrona Visconti; Eric Vicaut; Petr Widimsky
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

2.  Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Authors:  Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

3.  Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.

Authors:  L B Daniels; J A Parker; S R Patel; F Grodstein; S Z Goldhaber
Journal:  Am J Cardiol       Date:  1997-07-15       Impact factor: 2.778

4.  Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator.

Authors:  S Z Goldhaber; J E Markis; C M Kessler; M F Meyerovitz; D Kim; D E Vauchan; A P Selwyn; J Loscalzo; D L Dawley; G V Sharma
Journal:  Semin Thromb Hemost       Date:  1987-04       Impact factor: 4.180

5.  Catheter-directed, ultrasound-assisted thrombolysis is a safe and effective treatment for pulmonary embolism, even in high-risk patients.

Authors:  Kristen A Lee; Andrew Cha; Mark H Kumar; Combiz Rezayat; Clifford M Sales
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2017-01-12

6.  Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate and high-risk pulmonary embolism.

Authors:  Rolf P Engelberger; Aris Moschovitis; Jennifer Fahrni; Torsten Willenberg; Frederic Baumann; Nicolas Diehm; Do-Dai Do; Iris Baumgartner; Nils Kucher
Journal:  Eur Heart J       Date:  2013-12-13       Impact factor: 29.983

7.  Thrombolytic therapy delay is independent predictor of mortality in acute pulmonary embolism at emergency service.

Authors:  İnan Beydilli; Fevzi Yılmaz; Bedriye Müge Sönmez; Nalan Kozacı; Akar Yılmaz; İbrahim Halil Toksul; Ramazan Güven; Mustafa Avcı
Journal:  Kaohsiung J Med Sci       Date:  2016-11-01       Impact factor: 2.744

Review 8.  Thrombolytic therapy of acute pulmonary embolism: current status and future potential.

Authors:  S Z Goldhaber; M F Meyerovitz; J E Markis; D Kim; C M Kessler; G V Sharma; D E Vaughan; A P Selwyn; D L Dawley; J Loscalzo
Journal:  J Am Coll Cardiol       Date:  1987-11       Impact factor: 24.094

9.  Ultrasound-accelerated catheter-directed thrombolysis for acute submassive pulmonary embolism.

Authors:  Sandeep Bagla; John B Smirniotopoulos; Arletta van Breda; Michael J Sheridan; Keith M Sterling
Journal:  J Vasc Interv Radiol       Date:  2015-02-18       Impact factor: 3.464

10.  Safety and efficacy of ultrasound-accelerated catheter-directed lytic therapy in acute pulmonary embolism with and without hemodynamic instability.

Authors:  Madeline Nykamp; Angela VandenHull; Tyler Remund; Angelo Santos; Patrick Kelly; Greg Schultz; Chad Laurich
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2015-06-15
View more
  1 in total

1.  Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials.

Authors:  Zhi-Chun Gu; Yi-Dan Yan; Sheng-Yan Yang; Long Shen; Ling-Cong Kong; Chi Zhang; An-Hua Wei; Zheng Li; Xin-Hua Wang; Hou-Wen Lin
Journal:  Ann Transl Med       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.